During a Senate Foreign Relations Committee hearing on Tuesday, Sen. Marco Rubio (R-FL) asked the No. 2 at the State Department to consider trade policy when thinking about China.
If Rep. John Moolenaar (R-MI-2), the newly minted Chairman of the House Select Committee on the CCP, gets his wish, there won’t be any Chinese EV battery investments in the U.S.
The Department of Justice indicted a Chinese national who was living in the United States and importing thousands of kilograms of precursor chemicals used in making the addictive, powerful synthetic opioid known as fentanyl.
Should Sen. Sherrod Brown (D-OH) get his way, no Chinese EV can be driven within 25 miles of a Defense Department property, which likely means military housing, war colleges, and of course military bases.
Drug shortages are becoming commonplace in the U.S. Data from a new pharmaceutical industry tracking firm, Qyobo, shows hundreds of drugs are still in short supply – some well over a year — and our dependence on imports grows, including from labs on the receiving end of lackluster FDA inspections.
The de minimis customs provision that allows for goods priced under $800 to come into the U.S. duty free is full of risks, and an open door for “controlled substances and all sorts of contraband,” Homeland Security secretary Alejandro Mayorkas said on Tuesday.
China makes too many things. It would be great if they made it for their home market, but they do not. Instead, they massively subsidize their manufacturing companies and overproduce for the world – their main market being the United States.
The United States-Mexico-Canada (USMCA) Free Trade Agreement is fast becoming a free trade agreement for the world, whereas any multinational with a presence in Mexico can set up shop and make the U.S. its number one target. China is doing that now.
Domestic content rules and mandates have worked for China. Should the U.S. try to copy it, in spots, along key supply chains like new energy and semiconductors?